iMDK | PI3K/MDK Inhibitor | AmBeed-信号通路专用抑制剂

iMDK {[allProObj[0].p_purity_real_show]}

货号：A1209466

iMDK是一种 PI3K 抑制剂，能够抑制生长因子 MDK（中期因子/MK），在联合 MEK 抑制剂时能协同抑制非小细胞肺癌 (NSCLC)，同时对正常细胞和小鼠无明显毒性，具有癌症研究中的应用潜力。

iMDK 化学结构
CAS号：881970-80-5

iMDK 3D分子结构
CAS号：881970-80-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

PI3K 亚型比较

产品名称	C2β ↓ ↑	p110α ↓ ↑	p110β ↓ ↑	p110γ ↓ ↑	p110δ ↓ ↑	PI3K ↓ ↑	Vps34 ↓ ↑	其他靶点	纯度
A66	+ C2β, IC50: 462 nM	++ p110α, IC50: 32 nM							99%+
Taselisib	+ C2β, IC50: 292 nM	++++ PI3Kα, Ki: 0.29 nM	+++ PI3Kβ, Ki: 9.1 nM	++++ PI3Kγ, Ki: 0.97 nM	++++ PI3Kδ, Ki: 0.12 nM		+ hVps34, IC50: 374 nM		99%+
Gedatolisib		++++ PI3Kα, IC50: 0.4 nM		+++ PI3Kγ, IC50: 5.4 nM				mTOR	99%
HS-173		++++ PI3Kα , IC50: 0.8 nM							99%+
Serabelisib		+++ PI3Kα, IC50: 21 nM							99%+
GNE-477		++++ PI3Kα, IC50: 4 nM						mTOR	99%
YM-201636		+ p110α, IC50: 3.3 μM						PIKfyve	98%
AS-252424		+ PI3Kα, IC50: 935 nM		++ PI3Kγ, IC50: 33 nM					99%
Alpelisib		+++ PI3Kα, IC50: 5 nM							99%+
AS-604850		+ PI3Kα, IC50: 4.5 μM		+ PI3Kγ, IC50: 0.25 μM					99%
SF2523		++ PI3Kα, IC50: 34 nM		++ PI3Kγ, IC50: 158 nM				DNA-PK,mTOR	99%+
Inavolisib		++++ PI3K alpha, IC50: 0.038 nM							99%+
Bimiralisib		++++ PI3Kα, Kd: 1.5 nM	+++ PI3Kβ, Kd: 11 nM	++ PI3Kγ, Kd: 25 nM	++ PI3Kδ, Kd: 25 nM			mTOR	99%+
GSK1059615		++++ PI3Kα, IC50: 0.4 nM	++++ PI3Kβ, IC50: 0.6 nM	+++ PI3Kγ, IC50: 5 nM	++++ PI3Kδ, IC50: 2 nM			mTOR	98%
GSK2636771			✔						99%
Fimepinostat		+++ PI3Kα, IC50: 19 nM	++ PI3Kβ, IC50: 54 nM		++ PI3Kδ, IC50: 39 nM				99%+
VS-5584		++++ PI3Kα, IC50: 2.6 nM	+++ PI3Kβ, IC50: 21 nM	++++ PI3Kγ, IC50: 3.0 nM	++++ PI3Kδ, IC50: 2.7 nM			mTOR	98%
Dactolisib		++++ p110α1, IC50: 4 nM	++ p110β, IC50: 75 nM	+++ p110γ, IC50: 5 nM	+++ p110δ, IC50: 7 nM				98+%
PI-103		++++ p110α, IC50: 2 nM	++++ p110β, IC50: 3 nM	+++ p110γ, IC50: 15 nM	++++ p110δ, IC50: 3 nM			DNA-PK,mTOR	99%+
PI-3065			+ p110β, IC50: 1078 nM		+++ p110δ, IC50: 15 nM				99%+
Voxtalisib		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	99%+
AZD-8835		+++ PI3Kα, IC50: 6.2 nM	+ PI3Kβ, IC50: 431 nM	++ PI3Kγ, IC50: 90 nM	+++ PI3Kδ, IC50: 5.7 nM				99%
Pilaralisib analogue		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 36 nM	+++ PI3Kγ, IC50: 23 nM	++ PI3Kδ, IC50: 36 nM				99%+
ZSTK474		+++ PI3Kα, IC50: 16 nM	++ PI3Kβ, IC50: 44 nM	++ PI3Kγ, IC50: 49 nM	+++ PI3Kδ, IC50: 4.6 nM	++ PI3K, IC50: 37 nM			98%
AS-605240		++ PI3Kα, IC50: 60 nM	+ PI3Kβ, IC50: 270 nM	+++ PI3Kγ, IC50: 8 nM	+ PI3Kδ, IC50: 300 nM				98%
TGX-221			+++ p110β, IC50: 5 nM		++ p110δ, IC50: 0.1 μM				99%+
PF-04691502		++++ PI3Kα, Ki: 1.8 nM	++++ PI3Kβ, Ki: 2.1 nM	++++ PI3Kγ, Ki: 1.9 nM	++++ PI3Kδ, Ki: 1.6 nM			mTOR	98+%
GDC-0084		++++ PI3Kα, Ki app: 2 nM	++ PI3Kβ, Ki app: 46 nM	+++ PI3Kγ, Ki app: 10 nM	++++ PI3Kδ, Ki app: 3 nM			mTOR	99%+
Buparlisib		++ p110α, IC50: 52 nM	+ p110β, IC50: 166 nM	+ p110γ, IC50: 262 nM	++ p110δ, IC50: 116 nM		+ Vps34, IC50: 2.4 μM	mTOR	98%
LY294002		+ p110α, IC50: 0.5 μM	+ p110β, IC50: 0.97 μM		+ p110δ, IC50: 0.57 μM			DNA-PK	99%+
AZD 6482		+ PI3Kα, IC50: 870 nM	+++ PI3Kβ, IC50: 10 nM		++ PI3Kδ, IC50: 80 nM			DNA-PK	99%+
Pictilisib		++++ p110α, IC50: 3 nM	++ p110β, IC50: 33 nM	++ p110γ, IC50: 75 nM	++++ p110δ, IC50: 3 nM			mTOR	99%+
PKI-402		++++ PI3Kα, IC50: 2 nM	+++ PI3Kβ, IC50: 7 nM	+++ PI3Kγ, IC50: 16 nM	+++ PI3Kδ, IC50: 14 nM			mTOR	98%
Copanlisib		++++ PI3Kα, IC50: 0.5 nM	++++ PI3Kβ, IC50: 3.7 nM	+++ PI3Kγ, IC50: 6.4 nM	++++ PI3Kδ, IC50: 0.7 nM				99%+
Omipalisib		++++ p110α, Ki: 0.019 nM	++++ p110β, Ki: 0.13 nM	++++ p110γ, Ki: 0.06 nM	++++ p110δ, Ki: 0.024 nM				99%+
Izorlisib		+++ PI3Kα, IC50: 14 nM	++ PI3Kβ, IC50: 0.12 μM	++ PI3Kγ, IC50: 36 nM	+ PI3Kδ, IC50: 0.50 μM				99%+
AZD8186		++ PI3Kα, IC50: 35 nM	++++ PI3Kβ, IC50: 4 nM		+++ PI3Kδ, IC50: 12 nM				99%
KU-0060648		++++ PI3Kα, IC50: 4 nM	++++ PI3Kβ, IC50: 0.5 nM	+ PI3Kγ, IC50: 0.59 μM	++++ PI3Kδ, IC50: 0.1 nM			DNA-PK	98%
Apitolisib		+++ p110α, IC50: 5 nM	++ p110β, IC50: 27 nM	+++ p110γ, IC50: 14 nM	+++ p110δ, IC50: 7 nM			mTOR	98%+
CZC24832			+ PI3Kβ, IC50: 1.1 μM	++ PI3Kγ, IC50: 27 nM					98+%
BGT226 maleate		++++ PI3Kα, IC50: 4 nM	++ PI3Kβ, IC50: 63 nM	++ PI3Kγ, IC50: 38 nM				mTOR	99%+
TG 100713		++ PI3Kα, IC50: 165 nM	+ PI3Kβ, IC50: 215 nM	++ PI3Kγ, IC50: 50 nM	+++ PI3Kδ, IC50: 24 nM				98%+
PI3K-IN-1		++ PI3Kα, IC50: 39 nM	++ PI3Kβ, IC50: 113 nM	+++ PI3Kγ, IC50: 9 nM	++ PI3Kδ, IC50: 43 nM			DNA-PK,mTOR	98+%
TG100-115		+ PI3Kα, IC50: 1.3 μM	+ PI3Kβ, IC50: 1.2 μM	++ PI3Kγ, IC50: 83 nM	+ PI3Kδ, IC50: 235 nM				98%
PIK-90		+++ PI3Kα, IC50: 11 nM	+ PI3Kβ, IC50: 350 nM	+++ PI3Kγ, IC50: 18 nM	++ PI3Kδ, IC50: 58 nM				99%+
PIK-294			+ p110β, IC50: 490 nM	++ p110γ, IC50: 160 nM	+++ p110δ, IC50: 10 nM				99%+
Duvelisib			++++ PI3Kβ, Ki: 1564 pM	++ PI3Kγ, Ki: 243 pM	++++ PI3Kδ, Ki: 23 pM				99%+
GDC-0326		++++ PI3Kα, Ki: 0.2 nM	++ PI3Kβ, Ki: 26.6 nM	+++ PI3Kγ, Ki: 10.2 nM	++++ PI3Kδ, Ki: 4 nM				98%
Quercetin Dihydrate			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM				95%
Quercetin			+ PI3Kβ, IC50: 5.4 μM	+ PI3Kγ, IC50: 2.4 μM	+ PI3Kδ, IC50: 3.0 μM			PKC,Sirtuin,Src	95%
Leniolisib		+ PI3Kα, IC50: 0.244 μM	+ PI3Kβ, IC50: 0.424 μM	+ PI3Kγ, IC50: 2.23 μM	+++ PI3Kδ, IC50: 0.011 μM			DNA-PK	99%+
PIK-108			✔						99%
Eganelisib				+++ PI3Kγ, IC50: 16 nM					99%+
CAY10505				✔					99%
IPI-3063					++++ p110δ, IC50: 2.5 nM				99%
Nemiralisib					++++ PI3Kδ, pKi: 9.9				99%+
PF-4989216		++++ p110α, IC50: 2 nM		++ p110γ, IC50: 65 nM	++++ p110δ, IC50: 1 nM				99%+
PIK-75 HCl		+++ p110α, IC50: 5.8 nM		++ p110γ, IC50: 76 nM	+ p110δ, IC50: 0.51 μM			DNA-PK	99%+
Tenalisib				++ PI3Kγ, IC50: 33.2 nM	++ PI3Kδ, IC50: 24.5 nM				98%
Acalisib					+++ p110δ, IC50: 14 nM				99%+
Umbralisib					+++ PI3Kδ, IC50: 22.2 nM				99%+
AMG319				+ PI3Kγ, IC50: 850 nM	+++ PI3Kδ, IC50: 18 nM				99%
IC-87114				+ PI3Kγ, IC50: 29 μM	+ PI3Kδ, IC50: 0.5 μM				99%+
Idelalisib				++ p110γ, IC50: 89 nM	++++ p110δ, IC50: 2.5 nM				98%
PIK-293				+ p110γ, IC50: 10 μM	+ p110δ, IC50: 0.24 μM				99%+
Vps34-PIK-III					+ PI3Kδ, IC50: 1.2μM		+++ Vps34, IC50: 0.018μM		99%+
GSK2292767					✔				98%
Seletalisib				+ PI3Kγ, IC50: 282 nM	+++ PI3Kδ, IC50: 12 nM				99%+
P110δ-IN-1					++++ P110δ, IC50: 0.6 nM				99%
PI3Kδ-IN-5					++++ PI3Kδ, IC50: 0.9 nM				99%
SRX3207		+ PI3K alpha, IC50: 244 nM		+ PI3K gamma, IC50: 9790 nM	+ PI3K delta, IC50: 388 nM			Syk	98%
Parsaclisib HCl					++++ PI3Kδ, IC50: 1 nM				98%
IHMT-PI3Kδ-372					+++ PI3Kδ, IC50: 14 nM				98%
Trigonelline						✔		Akt	99%+
Wortmannin						++++ PI3K, IC50: 3 nM		MLCK,DNA-PK	99%+
Samotolisib						✔		DNA-PK	99%+
GNE-317						✔			99%+
Oroxin B						✔		Akt,PTEN	99%+
NU 7026						+ PI3K, IC50: 13 μM		DNA-PK	98+%
Deguelin						✔		Akt	99%+
Ailanthone						✔		ATM/ATR,Akt,CDK	98%
Resibufogenin						✔		ROS	98%
KU-57788						+ PI3K, IC50: 5 μM		DNA-PK,mTOR	99%+
Cinobufagine						✔		Akt	99%
α-Linolenic acid						✔			97% (GC)
MTX-211						✔		EGFR	98%
PI3K/mTOR Inhibitor-2						++++ PI3K, IC50: 3.4 nM		mTOR	99%+
SPP-86						✔			99%+
(E)-Akt inhibitor-IV						✔			98%
Vps34-IN-1							++ Vps34, IC50: 25 nM		98%
SAR405							++++ Vps34, IC50: 1.2 nM		98+%
3-Methyladenine				+ PI3Kγ, IC50: 60 μM			+ Vps34, IC50: 25 μM	Autophagy	98%
Vps34-IN-4							+++ VPS34, IC50: 15 nM		98%+
Autophinib							+++ Vps34, IC50: 19 nM	Autophagy	99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

iMDK 细胞实验

Cell Line MeT-5A MSTO-211H colon cancer cell line HCT116 breast cancer cell line BT549 cervical carcinoma cell line CaSki lung cancer cell line A549 kidney cancer cell line Caki-1 HUVEC cells A549 cells H520 cells H2009 cells H441 cells SKOV3 human ovarian cancer cell line SKOV3 human ovarian cancer cell line NHLF normal human lung fibroblast cells A549 lung adenocarcinoma cells H520 human lung squamous cell carcinoma cells H441 lung adenocarcinoma cells Caco-2 cells neural progenitors (NP) early neural progenitors (eNP) neural stem cells (NSC)	Concentration	Treated Time	Description	References
MeT-5A	7.5, 15, 50 µM	72 hours	To evaluate the effect of iMDK on the proliferation of MeT-5A cells, results showed significant inhibition of cell proliferation at the highest dose (50 µM).	Cancer Gene Ther. 2024 Nov;31(11):1708-1720
MSTO-211H	7.5, 15, 50 µM	72 hours	To evaluate the effect of iMDK on the proliferation of MSTO-211H cells, results showed significant inhibition of cell proliferation at the highest dose (50 µM).	Cancer Gene Ther. 2024 Nov;31(11):1708-1720
colon cancer cell line HCT116	100nM	48 hours	Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis	Front Oncol. 2022 Jun 7;12:885656
breast cancer cell line BT549	100nM	48 hours	Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis	Front Oncol. 2022 Jun 7;12:885656
cervical carcinoma cell line CaSki	100nM	48 hours	Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis	Front Oncol. 2022 Jun 7;12:885656
lung cancer cell line A549	100nM	48 hours	Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis	Front Oncol. 2022 Jun 7;12:885656
kidney cancer cell line Caki-1	100nM	48 hours	Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis	Front Oncol. 2022 Jun 7;12:885656
HUVEC cells	10 μM	5 hours	To evaluate the effect of iMDK on HUVEC tube formation, results showed that iMDK combined with PD0325901 significantly inhibited tube formation	Exp Cell Res. 2015 Jul 15;335(2):197-206
A549 cells	0.25 μM	72 hours	To evaluate the inhibitory effect of iMDK on A549 cell proliferation, results showed that iMDK alone did not inhibit cell proliferation, but significantly inhibited cell proliferation when combined with PD0325901	Exp Cell Res. 2015 Jul 15;335(2):197-206
H520 cells	0.125 μM	72 hours	To evaluate the inhibitory effect of iMDK on H520 cell proliferation, results showed that iMDK significantly inhibited cell proliferation	Exp Cell Res. 2015 Jul 15;335(2):197-206
H2009 cells	1 μM	24 hours	To evaluate the effect of iMDK on H2009 cell colony formation, results showed that iMDK significantly reduced colony formation	Exp Cell Res. 2015 Jul 15;335(2):197-206
H441 cells	2.5 μM	72 hours	To evaluate the inhibitory effect of iMDK on H441 cell proliferation, results showed that iMDK significantly inhibited cell proliferation	Exp Cell Res. 2015 Jul 15;335(2):197-206
SKOV3 human ovarian cancer cell line	100 nM		To assess the effect of iMDK on IFN-γ-induced EMT and metastasis, found that iMDK significantly suppressed IFN-γ-driven EMT and metastasis	Biomedicines. 2022 Dec 21;11(1):8
SKOV3 human ovarian cancer cell line	6.6 nM	48 hours	To assess the effect of iMDK on IFN-γ-induced anti-proliferation, found that iMDK significantly enhanced the anti-tumor activity of IFN-γ	Biomedicines. 2022 Dec 21;11(1):8
NHLF normal human lung fibroblast cells	5-500 nM	48 hours	iMDK had no significant effect on NHLF cells	PLoS One. 2013 Aug 16;8(8):e71093
A549 lung adenocarcinoma cells	5-500 nM	48 hours	iMDK had no significant effect on A549 cells	PLoS One. 2013 Aug 16;8(8):e71093
H520 human lung squamous cell carcinoma cells	5-500 nM	48 hours	iMDK inhibited H520 cell growth	PLoS One. 2013 Aug 16;8(8):e71093
H441 lung adenocarcinoma cells	5-500 nM	48 hours	iMDK inhibited H441 cell growth by suppressing the PI3K pathway and inducing apoptosis	PLoS One. 2013 Aug 16;8(8):e71093
Caco-2 cells	25 nM	72 hours	To investigate the effect of iMDK on the permeability of tight junctions in MPA-treated Caco-2 cell monolayers. Results showed that iMDK significantly inhibited MPA-induced compromised TJ integrity.	Front Physiol. 2017 Jun 26;8:438
neural progenitors (NP)	0.5 μM	5 days	Evaluate the effect of idebenone on NP cell viability, showing no significant change at 0.5 μM concentration.	Biogerontology. 2017 Aug;18(4):665-677
early neural progenitors (eNP)	0.5 μM	5 days	Evaluate the effect of idebenone on eNP cell viability, showing a significant increase to 138.19% at 0.5 μM concentration.	Biogerontology. 2017 Aug;18(4):665-677
neural stem cells (NSC)	0.5 μM	5 days	Evaluate the effect of idebenone on NSC cell viability, showing a significant increase to 130% at 0.5 μM concentration.	Biogerontology. 2017 Aug;18(4):665-677

Cell Line

Concentration

Treated Time

Description

References

MeT-5A

7.5, 15, 50 µM

72 hours

To evaluate the effect of iMDK on the proliferation of MeT-5A cells, results showed significant inhibition of cell proliferation at the highest dose (50 µM).

Cancer Gene Ther. 2024 Nov;31(11):1708-1720

MSTO-211H

7.5, 15, 50 µM

72 hours

To evaluate the effect of iMDK on the proliferation of MSTO-211H cells, results showed significant inhibition of cell proliferation at the highest dose (50 µM).

Cancer Gene Ther. 2024 Nov;31(11):1708-1720

colon cancer cell line HCT116

100nM

48 hours

Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis

Front Oncol. 2022 Jun 7;12:885656

breast cancer cell line BT549

100nM

48 hours

Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis

Front Oncol. 2022 Jun 7;12:885656

cervical carcinoma cell line CaSki

100nM

48 hours

Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis

Front Oncol. 2022 Jun 7;12:885656

lung cancer cell line A549

100nM

48 hours

Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis

Front Oncol. 2022 Jun 7;12:885656

kidney cancer cell line Caki-1

100nM

48 hours

Inhibited MDK expression, reversed IFN-γ-activated EMT and tumor metastasis

Front Oncol. 2022 Jun 7;12:885656

HUVEC cells

10 μM

5 hours

To evaluate the effect of iMDK on HUVEC tube formation, results showed that iMDK combined with PD0325901 significantly inhibited tube formation

Exp Cell Res. 2015 Jul 15;335(2):197-206

A549 cells

0.25 μM

72 hours

To evaluate the inhibitory effect of iMDK on A549 cell proliferation, results showed that iMDK alone did not inhibit cell proliferation, but significantly inhibited cell proliferation when combined with PD0325901

Exp Cell Res. 2015 Jul 15;335(2):197-206

H520 cells

0.125 μM

72 hours

To evaluate the inhibitory effect of iMDK on H520 cell proliferation, results showed that iMDK significantly inhibited cell proliferation

Exp Cell Res. 2015 Jul 15;335(2):197-206

H2009 cells

1 μM

24 hours

To evaluate the effect of iMDK on H2009 cell colony formation, results showed that iMDK significantly reduced colony formation

Exp Cell Res. 2015 Jul 15;335(2):197-206

H441 cells

2.5 μM

72 hours

To evaluate the inhibitory effect of iMDK on H441 cell proliferation, results showed that iMDK significantly inhibited cell proliferation

Exp Cell Res. 2015 Jul 15;335(2):197-206

SKOV3 human ovarian cancer cell line

100 nM

To assess the effect of iMDK on IFN-γ-induced EMT and metastasis, found that iMDK significantly suppressed IFN-γ-driven EMT and metastasis

Biomedicines. 2022 Dec 21;11(1):8

SKOV3 human ovarian cancer cell line

6.6 nM

48 hours

To assess the effect of iMDK on IFN-γ-induced anti-proliferation, found that iMDK significantly enhanced the anti-tumor activity of IFN-γ

Biomedicines. 2022 Dec 21;11(1):8

NHLF normal human lung fibroblast cells

5-500 nM

48 hours

iMDK had no significant effect on NHLF cells

PLoS One. 2013 Aug 16;8(8):e71093

A549 lung adenocarcinoma cells

5-500 nM

48 hours

iMDK had no significant effect on A549 cells

PLoS One. 2013 Aug 16;8(8):e71093

H520 human lung squamous cell carcinoma cells

5-500 nM

48 hours

iMDK inhibited H520 cell growth

PLoS One. 2013 Aug 16;8(8):e71093

H441 lung adenocarcinoma cells

5-500 nM

48 hours

iMDK inhibited H441 cell growth by suppressing the PI3K pathway and inducing apoptosis

PLoS One. 2013 Aug 16;8(8):e71093

Caco-2 cells

25 nM

72 hours

To investigate the effect of iMDK on the permeability of tight junctions in MPA-treated Caco-2 cell monolayers. Results showed that iMDK significantly inhibited MPA-induced compromised TJ integrity.

Front Physiol. 2017 Jun 26;8:438

neural progenitors (NP)

0.5 μM

5 days

Evaluate the effect of idebenone on NP cell viability, showing no significant change at 0.5 μM concentration.

Biogerontology. 2017 Aug;18(4):665-677

early neural progenitors (eNP)

0.5 μM

5 days

Evaluate the effect of idebenone on eNP cell viability, showing a significant increase to 138.19% at 0.5 μM concentration.

Biogerontology. 2017 Aug;18(4):665-677

neural stem cells (NSC)

0.5 μM

5 days

Evaluate the effect of idebenone on NSC cell viability, showing a significant increase to 130% at 0.5 μM concentration.

Biogerontology. 2017 Aug;18(4):665-677

iMDK 动物实验

Species Nude mice BALB/c nude mice BALB/c nude mice	Animal Model Xenograft model H441 cell xenograft model H441 lung adenocarcinoma xenograft model	Administration	Dosage	Frequency	Description	References
Nude mice	Xenograft model	Intraperitoneal injection	9 mg/kg	Once every two days	IMDK significantly reduced tumor volume and weight and decreased lung metastasis rates	Cancers (Basel). 2020 Aug 24;12(9):2402
BALB/c nude mice	H441 cell xenograft model	IMDK: intraperitoneal injection, PD0325901: oral administration	iMDK: 9 mg/kg, PD0325901: 5 mg/kg	IMDK: once daily, PD0325901: five times per week, for 11 days	To evaluate the inhibitory effect of iMDK combined with PD0325901 on H441 cell xenograft tumor growth, results showed that the combination therapy significantly inhibited tumor growth and tumor-associated angiogenesis	Exp Cell Res. 2015 Jul 15;335(2):197-206
BALB/c nude mice	H441 lung adenocarcinoma xenograft model	Intraperitoneal injection	9 mg/kg	3 or 5 times per week for 10 days	IMDK significantly inhibited tumor growth by suppressing the PI3K pathway and inducing apoptosis	PLoS One. 2013 Aug 16;8(8):e71093

Species

Nude mice BALB/c nude mice BALB/c nude mice

Animal Model

Xenograft model H441 cell xenograft model H441 lung adenocarcinoma xenograft model

Administration

Dosage

Frequency

Description

References

Nude mice

Xenograft model

Intraperitoneal injection

9 mg/kg

Once every two days

IMDK significantly reduced tumor volume and weight and decreased lung metastasis rates

Cancers (Basel). 2020 Aug 24;12(9):2402

BALB/c nude mice

H441 cell xenograft model

IMDK: intraperitoneal injection, PD0325901: oral administration

iMDK: 9 mg/kg, PD0325901: 5 mg/kg

IMDK: once daily, PD0325901: five times per week, for 11 days

To evaluate the inhibitory effect of iMDK combined with PD0325901 on H441 cell xenograft tumor growth, results showed that the combination therapy significantly inhibited tumor growth and tumor-associated angiogenesis

Exp Cell Res. 2015 Jul 15;335(2):197-206

BALB/c nude mice

H441 lung adenocarcinoma xenograft model

Intraperitoneal injection

9 mg/kg

3 or 5 times per week for 10 days

IMDK significantly inhibited tumor growth by suppressing the PI3K pathway and inducing apoptosis

PLoS One. 2013 Aug 16;8(8):e71093

iMDK 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.28mL

2.66mL

1.33mL

26.57mL

5.31mL

2.66mL

iMDK 技术信息

CAS号	881970-80-5
分子式	C₂₁H₁₃FN₂O₂S
分子量	376.4
SMILES Code	O=C1C(C2=CN3C(SC(CC4=CC=C(F)C=C4)=C3)=N2)=CC5=C(O1)C=CC=C5

别名
运输	蓝冰

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 3 mg/mL(7.97 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

iMDK {[allProObj[0].p_purity_real_show]}

iMDK 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

iMDK 质控信息

iMDK 细胞实验

iMDK 动物实验

iMDK 实验方案

iMDK 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

iMDK {[allProObj[0].p_purity_real_show]}

iMDK 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

iMDK 质控信息

iMDK 细胞实验

iMDK 动物实验

iMDK 实验方案

iMDK 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

iMDK 纯度/质量文件产品仅供科研